寶萊特(300246.SZ):出口收入主要以監護儀產品收入為主
格隆匯11月19日丨寶萊特(300246.SZ)在投資者關係表示,以上年度為例,公司2023年出口收入為2.48億元,約佔營業收入的21%;內銷收入為9.3億元,約佔營業收入的78%(數據按四捨五入計算)。公司出口收入主要以監護儀產品收入為主,血透系列產品也有出口業務,其中血液透析設備、透析器、透析液過濾器等產品已在海外銷售。目前公司外銷主導產品均通過了歐盟CE認證、美國FDA510(k)許可、美國NRTL產品認證和加拿大產品許可證書等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.